Key result
Common and rare genetic variants in platelet surface receptors may contribute to ischemic stroke risk and abnormal platelet response to antiplatelet drugs.
Why the study?
Do common genetic variants in platelet surface receptors influence the risk of ischemic stroke and response to antiplatelet therapies?
Do common genetic variants in platelet surface receptors influence the risk of ischemic stroke and response to antiplatelet therapies?
Genetic variants in platelet surface receptors may contribute to ischemic stroke risk and variability in response to antiplatelet therapies.
Platelet phenotype variability may affect antiplatelet response in stroke; hypothesis-generating for pharmacogenomics and requires prospective validation.
Ischemic stroke has been named one of the leading causes of death worldwide. Whereas numerous biological mechanisms and molecules were found to be associated with stroke, platelets are particularly contributive to its pathogenesis. Recent data indicate considerable variability in platelet phenotype which accounts for differences in platelet surface receptor function, count and reactivity. These features collectively influence both the events leading to a disease and effectiveness of antiplatelet therapies. Consequently, genetic variants predisposing to cerebrovascular diseases can be sequenced using a wide array of techniques and become a useful tool in clinical setting. In this review, we provide an outline of common platelet polymorphisms that impose risk on ischemic stroke development and should be evaluated as targets to improve treatment. As study results are often inconsistent, partly due to differences in demographic characteristics between study populations and the fact that the functional impact of these variants has been relatively small, we conclude that both rare, low-frequency and common variants might account for genetic contribution on abnormal platelet response to antiplatelet drugs.
No takes yet. Share an insight, caveat, or question.
Milanowski et al. (2016) conducted a review in Ischemic stroke. Genetic variants in platelet surface receptors was evaluated on Ischemic stroke development and abnormal platelet response to antiplatelet drugs. Common and rare genetic variants in platelet surface receptors may contribute to ischemic stroke risk and abnormal platelet response to antiplatelet drugs.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: